← Back to Search

Remote CGM Monitoring for Type 1 Diabetes

N/A
Waitlist Available
Led By Priya Prahalad, MD, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age: birth to < 21 years of age
Be younger than 65 years old
Must not have
Diabetes diagnosis other than T1D
Individuals > 21 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether increased contact between patients and their care team can improve diabetes outcomes. Continuous glucose monitor data will be used to proactively reach out to patients and their families for more frequent dose adjustments.

Who is the study for?
This trial is for children and young adults up to 21 years old who have been newly diagnosed with Type 1 Diabetes within the last month. Participants must be seen at Stanford Children's Diabetes Clinic, agree to share their continuous glucose monitor (CGM) data for remote monitoring, and plan to continue their follow-up care at the same clinic.
What is being tested?
The study aims to see if more contact between patients and healthcare providers through a system called GluVue can help manage diabetes better in the first year after diagnosis. This involves integrating CGM data into the patient's electronic medical record for closer monitoring.
What are the potential side effects?
Since this trial focuses on remote monitoring of existing CGM devices rather than testing new medications or treatments, there are no direct side effects from interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am younger than 21 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with a type of diabetes that is not Type 1.
Select...
I am over 21 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Contacts with the care provider
Secondary study objectives
Hemoglobin A1c

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with Type 1 DiabetesExperimental Treatment1 Intervention
Participants will wear a continuous glucose monitor (CGM) and receive remote monitoring of the CGM data by the clinical care team.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,484 Previous Clinical Trials
17,516,021 Total Patients Enrolled
Priya Prahalad, MD, PhDPrincipal InvestigatorStanford University

Media Library

Remote Monitoring of CGM Data Clinical Trial Eligibility Overview. Trial Name: NCT03968055 — N/A
Type 1 Diabetes Research Study Groups: Patients with Type 1 Diabetes
Type 1 Diabetes Clinical Trial 2023: Remote Monitoring of CGM Data Highlights & Side Effects. Trial Name: NCT03968055 — N/A
Remote Monitoring of CGM Data 2023 Treatment Timeline for Medical Study. Trial Name: NCT03968055 — N/A
~15 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top